Article Text
Miscellaneous
Development of a new mutation in EGFR leads to drug resistance in non-small cell lung cancer
Statistics from Altmetric.com
Epidermal growth factor receptor (EGFR) is frequently overexpressed and in an activated phosphorylated form in non-small-cell lung cancers (NSCLC). Response rates of 10–20% can be achieved with the use of anilinoquinazoline tyrosine kinase inhibitors targeted against EGFR although most patients eventually relapse. The majority of responsive tumours contain somatic mutations …